Aspira Women's Health Inc. - Common Stock (AWH)

Competitors to Aspira Women's Health Inc. - Common Stock (AWH)

Exact Sciences Corporation 

Exact Sciences is primarily known for its innovative cancer screening tests, such as Cologuard for colorectal cancer. Although their primary focus is not specifically women's health, some of their products intersect with women's health concerns. They compete with Aspira indirectly by leveraging their expertise in biomarker development and testing, which could conceivably extend to ovarian cancer screening in the future, thereby posing a potential competitive threat based on their robust research and resources.

Fulgent Genetics, Inc. 

Fulgent Genetics offers a wide range of genetic testing services, including tests relevant to women's health issues. They compete with Aspira by appealing to healthcare providers who are looking for comprehensive panels that can diagnose a variety of genetic conditions. Fulgent’s established network and technological capabilities position them as a solid competitor, but they may not be as niche-focused as Aspira in women's health specifically.

GeneDx

GeneDx specializes in genomic testing for rare and undiagnosed diseases, including those affecting women's health. They compete with Aspira by offering extensive genetic insights that can help in the early detection and treatment of various conditions. While GeneDx is more focused on broader genetic testing services, their capabilities in hereditary disease testing provide competitive pressure on Aspira, especially in targeting specific niche markets.

Invitae Corporation

Invitae provides a broad spectrum of genetic testing services with a significant focus on women's health-related genetics, including reproductive health and hereditary cancer testing. They compete with Aspira by offering similar diagnostic tests that assess cancer risk. Invitae has a competitive advantage through its extensive test library and established relationships with healthcare providers, making them a formidable competitor in the genetic testing marketplace.

Myriad Genetics, Inc. 

Myriad Genetics is a leader in genetic testing and offers a range of tests for women's health, including hereditary cancer testing. They compete with Aspira Women's Health by providing women with insights into their genetic predispositions to various health conditions, particularly ovarian and breast cancers, which is a key focus of Aspira. Myriad's established reputation and comprehensive testing portfolio give it a competitive edge over newer entrants like Aspira.